Literature DB >> 17383195

Cyclin-dependent kinases: molecular switches controlling anergy and potential therapeutic targets for tolerance.

Andrew D Wells1.   

Abstract

A large body of research has established the importance of costimulatory signals and proliferation for the generation of productive T cell immune responses. While costimulation and cell cycle progression are each individually necessary for CD4+ effector T cell differentiation, it has become clear that neither of these processes alone is sufficient to avoid anergy. This review outlines the links between T cell differentiation, tolerance, and the cell cycle, and highlights recent work that has implicated cyclin-dependent kinases as important regulators and potential targets for modulation of T cell immunity and tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383195      PMCID: PMC1949497          DOI: 10.1016/j.smim.2007.02.009

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  64 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

2.  Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity.

Authors:  H Gudmundsdottir; A D Wells; L A Turka
Journal:  J Immunol       Date:  1999-05-01       Impact factor: 5.422

3.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.

Authors:  J D Powell; C G Lerner; R H Schwartz
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

4.  Opposing roles for the cyclin-dependent kinase inhibitor p27kip1 in the control of CD4+ T cell proliferation and effector function.

Authors:  Emily A Rowell; Matthew C Walsh; Andrew D Wells
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

5.  Signals from CD28 induce stable epigenetic modification of the IL-2 promoter.

Authors:  Rajan M Thomas; Ling Gao; Andrew D Wells
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

6.  Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1.

Authors:  Xiangao Huang; Maurizio Di Liberto; Adam F Cunningham; Lin Kang; Shuhua Cheng; Scott Ely; Hsiou-chi Liou; Ian C M Maclennan; Selina Chen-Kiang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-10       Impact factor: 11.205

Review 7.  Targeting cell cycle and apoptosis for the treatment of human malignancies.

Authors:  Adrian M Senderowicz
Journal:  Curr Opin Cell Biol       Date:  2004-12       Impact factor: 8.382

8.  Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine.

Authors:  Nikolay O Bukanov; Laurie A Smith; Katherine W Klinger; Steven R Ledbetter; Oxana Ibraghimov-Beskrovnaya
Journal:  Nature       Date:  2006-11-22       Impact factor: 49.962

9.  A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory.

Authors:  Akiko Murayama; Kazuhisa Sakura; Mina Nakama; Kayoko Yasuzawa-Tanaka; Etsuko Fujita; Yukiyo Tateishi; Yinan Wang; Toshikazu Ushijima; Tadashi Baba; Kazuko Shibuya; Akira Shibuya; Yoh-ichi Kawabe; Junn Yanagisawa
Journal:  EMBO J       Date:  2006-02-23       Impact factor: 11.598

10.  Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.

Authors:  Adriano G Rossi; Deborah A Sawatzky; Annemieke Walker; Carol Ward; Tara A Sheldrake; Nicola A Riley; Alison Caldicott; Magdalena Martinez-Losa; Trevor R Walker; Rodger Duffin; Mohini Gray; Elvira Crescenzi; Morag C Martin; Hugh J Brady; John S Savill; Ian Dransfield; Christopher Haslett
Journal:  Nat Med       Date:  2006-09-03       Impact factor: 53.440

View more
  10 in total

1.  The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.

Authors:  Anoma Nellore; Bianling Liu; Nikolaos Patsoukis; Vassiliki A Boussiotis; Lequn Li
Journal:  Clin Immunol       Date:  2014-03-12       Impact factor: 3.969

Review 2.  New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation.

Authors:  Andrew D Wells; Peter A Morawski
Journal:  Nat Rev Immunol       Date:  2014-03-07       Impact factor: 53.106

3.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

Review 4.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 5.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 6.  Biochemical signaling of PD-1 on T cells and its functional implications.

Authors:  Vassiliki A Boussiotis; Pranam Chatterjee; Lequn Li
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

7.  Cyclin-dependent kinase 2 controls peripheral immune tolerance.

Authors:  Neelanjana Chunder; Liqing Wang; Chunxia Chen; Wayne W Hancock; Andrew D Wells
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

8.  CD4+CD25+ T regulatory cells from FIV+ cats induce a unique anergic profile in CD8+ lymphocyte targets.

Authors:  Jonathan E Fogle; Wayne A Tompkins; Mary B Tompkins
Journal:  Retrovirology       Date:  2010-11-19       Impact factor: 4.602

9.  Biological targets for isatin and its analogues: Implications for therapy.

Authors:  Alexei Medvedev; Olga Buneeva; Vivette Glover
Journal:  Biologics       Date:  2007-06

10.  Protein kinase C signaling and cell cycle regulation.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Front Immunol       Date:  2013-01-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.